Discover the complementary MOAs of ROCKLATAN®
(netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%
The problem of reduced outflow
In open-angle glaucoma patients, IOP becomes elevated when the trabecular meshwork becomes fibrotic and aqueous humor outflow is reduced.1
- The trabecular meshwork is integral to the regulation of aqueous humor outflow and IOP2
- Cellular damage due to glaucoma (eg, oxidative stress) may result in stiffness of the trabecular meshwork3
- This may impede the outflow of aqueous humor and result in persistently high IOP3
ROCKLATAN® contains latanoprost and netarsudil, which reduce IOP by increasing aqueous humor outflow through the conventional and unconventional pathways4
IOP=Intraocular pressure;
MOAs=Mechanisms of action.
REFERENCES
1. Winkler NS, Fautsch MP. Effects of prostaglandin analogues on aqueous humor outflow pathways. J Ocul Pharmacol Ther. 2014;30(2-3):102-109.
2. Saccà SC, Pulliero A, Izzotti A. The dysfunction of the trabecular meshwork during glaucoma course. J Cell Physiol. 2014;230:510-525.
3. Ren R, Li G, Duong Le T, Kopczynski C, Stamer WD, Gong H. Netarsudil increases outflow facility in human eyes through multiple mechanisms. Invest Ophthalmol Vis Sci. 2016;57(14):6197-6209.
4. Brubaker JW, Teymoorian S, Lewis RA, et al. One year of netarsudil and latanoprost fixed-dose combination for elevated intraocular pressure: phase 3, randomized MERCURY-1 study. Ophthalmol Glaucoma. 2020;3(5):327-338.
IMPORTANT SAFETY INFORMATION
Contraindications
None.
Warnings and Precautions
- Increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes can occur. Iris pigmentation likely to be permanent.
INDICATIONS AND USAGE
ROCKLATAN® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
- Gradual change to eyelashes may include increased length, thickness, number, and misdirected growth of lashes. Usually reversible upon discontinuation of treatment.
- Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). Should generally not be used in patients with active intraocular inflammation.
- Macular edema, including cystoid macular edema, has been reported with latanoprost. Use with caution in aphakic patients, pseudophakic patients with a torn posterior lens capsule, or patients with known risk factors for macular edema.
- Use with caution in patients with a history of herpetic keratitis. Avoid use in cases of active herpes simplex keratitis.
- Bacterial keratitis has been reported with multiple-dose containers of topical ophthalmic products inadvertently contaminated by patients.
- Remove contact lenses prior to administration and reinsert 15 minutes after administration.
INDICATIONS AND USAGE
ROCKLATAN® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Adverse Reactions
The most common ocular adverse reactions were conjunctival hyperemia (59%), with 5% of patients discontinuing therapy for this reason, instillation site pain (20%), corneal verticillata (15%), and conjunctival hemorrhage (11%). Eye pruritus, visual acuity reduced, increased lacrimation, instillation site discomfort, and blurred vision were reported in 5-8% of patients.
DOSAGE AND ADMINISTRATION
The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. The dosage of ROCKLATAN® should not exceed once daily. ROCKLATAN® may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.
Please click here for full prescribing information for ROCKLATAN® Solution.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.